Press Release: Natera to Report its Third Quarter Results on November 6, 2025

Dow Jones
2025/10/30
AUSTIN, Texas--(BUSINESS WIRE)--October 30, 2025-- 

Natera, Inc. $(NTRA)$, a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September 30, 2025, after the market closes on November 6, 2025. Natera will host a conference call and webcast shortly thereafter at 4:30 p.m. ET.

 
Earnings Conference Call Information 
Event:            Natera's Third Quarter 2025 Financial Results 
Date:             November 6, 2025 
Time:             4:30 p.m. ET 
Live Dial-In:     1-888-770-7321 (Domestic) 
                  1-929-201-7107 (International) 
Conference ID:    7684785 
Webcast:          https://events.q4inc.com/attendee/822764987 
 

A webcast replay will be available at investor.natera.com.

About Natera

Natera$(TM)$ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 325 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments $(CLIA)$ in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251030336447/en/

 
    CONTACT:    Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com 

Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

 
 

(END) Dow Jones Newswires

October 30, 2025 07:06 ET (11:06 GMT)

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10